Clinical trial

A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA…

NCT00001088 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed

Key facts

NCT number NCT00001088
Title A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers
Official title A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers
Lead sponsor National Institute of Allergy and Infectious Diseases (NIAID), NIH
Status Completed
Phase Phase 1
Study type Interventional
Conditions HIV Infections
Intervention type Biological, Drug
Interventions APL 400-047, Bupivacaine hydrochloride
Enrollment 40
Start date Jul 1, 1997
Primary completion Feb 1, 2001
Completion Feb 1, 2001
First posted Aug 31, 2001
Last update posted Sep 29, 2008
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies